ABSTRACT
Introduction The burden of cardiovascular disease (CVDs), in the number of premature deaths, continues to increase globally and alarmingly, especially in almost all countries outside high-income countries. An accurate estimate of premature CVD death is of crucial importance for planning, implementing, and evaluating cardiovascular prevention and care interventions. However, existing literature reported the evidence on premature CVD death from selected regions, and there has been less evidence of systematic review with meta-analysis estimating the global premature death. This paper reports the protocol for a systematic review and meta-analysis to derive solid and updated estimates on global and setting-specific premature CVD death prevalence and its associated risk factors.
Methods and analysis PUBMED, EMBASE, Web of Science, CINAHL, and Cochrane Central Register of Controlled Trials (CENTRAL) will be used as the literature database. Retrieved records will be independently screened by two authors and relevant data will be extracted from studies that report data on premature mortality (death before the age of 70 years) related to CVD. Study selection and reporting will follow the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guideline. Pooled estimates of premature CVD mortality (based on standardised mortality ratio and years of life lost) and the effect size of modifiable risk factors will be computed applying random-effects meta-analysis. Heterogeneity among selected studies will be assessed using the I2 statistic and explored through meta-regression and subgroup analyses. Depending on data availability, we propose to conduct subgroup analyses by geographical area, CVD events, and socio-demographic variables of interest study. The risk of bias for the studies included in the systematic review or meta-analysis will be assessed by the Newcastle–Ottawa Quality Assessment Scale.
Ethics and dissemination Ethics approval is not required as the data used in this systematic review will be extracted from published studies. The systematic review will focus on the premature CVD mortality rate and its associated factors. The findings of the final report will be disseminated to the scientific community through publication in a peer-reviewed journal and presentation at conferences.
PROSPERO registration number CRD42021288415
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Ministry of Health Malaysia
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
